Blood Filtration Offers Hope in the Fight Against Pancreatic Cancer
18 Julio 2024 - 12:20PM
Business Wire
Study Suggests ExThera Medical’s Seraph® 100
Technology Can Reduce the Spread of Cancer Cells
In a groundbreaking advancement of a novel cancer treatment,
researchers have successfully deployed Seraph® 100 blood filtration
media to demonstrate removal of Circulating Tumor Cells (CTCs) from
the blood of patients suffering from advanced pancreatic cancer.
The published results are foundational for ExThera Medical’s
innovative circulating tumor cell reducing device, the ONCObind™
Procedure Hemoperfusion Filter (ONCObind™), to pave the way for
improved longevity and better outcomes by reducing or eliminating
cancer metastasis. ONCObind™ uses the Seraph® 100 filtration media
to filter circulating tumor cells from the blood.
Many cancers become deadly when they spread from their original
site to other parts of the body. CTCs, which travel through the
bloodstream, play a critical role in metastatic cancer. By removing
these cells, ExThera Medical’s ONCObind offers a promising approach
to interrupting this spread, for longer patient survival.
The hemoperfusion media demonstrated significant reduction of
circulating tumor cells in patient blood samples. Authors of the
paper further suggested that blood purification using Seraph® 100
media may be considered a pioneering novel therapy for PDAC, either
alone or in combination with existing therapies. Additionally, they
asserted that the results of this study may also be relevant for
establishing treatment procedures for other cancers, as they
postulated that reducing metastatic potential of the disease may
improve survival.
"By removing CTCs, we can potentially interrupt the metastatic
process and improve patient outcomes," according to the lead
researcher on the study, Dr. Peter Kuhn, PhD, Founding Director of
the USC Michelson Convergent Science Institute of Cancer, and
coauthor of the publication. "This device represents an opportunity
to significantly improve the care for patients with pancreatic
cancer and is potentially applicable to other forms of cancer."
In the study, blood samples of patients with pancreatic ductal
adenocarcinoma (PDAC) underwent in vitro blood filtration using the
Seraph® 100 media. The results showed a significant reduction in
CTCs, suggesting an oncology focused product could be used as a
therapeutic tool either alone or in conjunction with other cancer
treatments such as chemotherapy and radiation.
"The potential of this device to extend and improve the lives of
cancer patients is immense," said Erin Borger, CEO of ExThera
Medical. "Researchers observed on average a 94% reduction in
circulating tumor cells with a single use of our technology. We are
eager to continue our research and see the impact it can have on
patient care."
The results of the study were published in Nature’s BJC
Reports.
About ExThera Medical Corporation
ExThera Medical Corporation develops and commercializes
extracorporeal blood filtration devices, including the Seraph®
100 MicroBind® Affinity Blood Filter for removing a broad range
of pathogens from the bloodstream of patients. Seraph® 100 can be
used in hospitals, clinics, on battlefields and in other austere
environments to address nosocomial and community-acquired
infections as well as those caused by battlefield wounds,
pandemics, and biological warfare agents. ExThera Medical’s
extracorporeal products have demonstrated life-saving capabilities
in a wide range of critically ill patients suffering from sepsis,
COVID-19, and many other severe bloodstream infections. With a
growing body of outcome and health economic evidence from
independent clinical studies, success in the DARPA Dialysis-Like
Therapeutics program, and from successful clinical use in the US,
the EU, and the Middle East, the company is well positioned to
serve healthcare professionals and patients alike. The Seraph® 100
attained CE Mark and is commercially available in the EU under a
broad Indication For Use. The Seraph® 100 has FDA Emergency Use
Authorization (EUA) for treatment of COVID-19 in the USA.
For more information, visit the company’s website at
www.extheramedical.com.
About Seraph® 100 and the ONCObind Procedure
As a patient’s blood flows through the Seraph® 100 filter, it
passes through a bed of small beads with receptors that mimic the
receptors on human cells that pathogens target when they invade the
body. Many harmful substances are quickly captured and adsorbed
onto the surface of the beads and are thereby subtracted from the
bloodstream. Seraph® adds nothing to the bloodstream. It targets
the pathogens that cause the infection, while it also binds and
removes harmful substances generated by the pathogen and by the
body’s response to the infection. Seraph’s proprietary adsorption
media (the beads) constitute a flexible platform that uses
immobilized (chemically bonded) heparin for its well-established
blood compatibility and its unique ability to bind circulating
tumor cells, bacteria, viruses, fungi, and important sepsis
mediators reported to contribute to organ failure during
sepsis.
ExThera Medical is currently developing the ONCObind™ Procedure
Hemoperfusion Filter (ONCObind™) to support cancer treatment.
ONCObind™ is part of the same platform technology as Seraph®
100.
For more news stories on Seraph® 100 and ONCObind™, click
here.
Disclaimer
All information contained in this news release derives from
plausible, reliable sources which, however, have not been
independently examined. There is no warranty, confirmation or
guarantee, and no responsibility or liability is taken concerning
correctness or completeness. As far as it is allowed by the
relevant law, no liability whatsoever is taken on for any direct or
indirect loss caused by the deployment of this news release or its
contents. This communication includes forward-looking statements
regarding events, trends and business prospects that may affect our
future operating results and financial position. Such statements
are subject to risks and uncertainties that could cause our actual
results and financial position to differ materially. The investment
and/or the revenues that arise from it can rise or fall. A total
loss is possible. Persons who are in possession of this news
release are requested to obtain information concerning possible
legal limitations and to observe them accordingly. We assume no
responsibility to update or revise any forward-looking statements
contained in this news release to reflect events, trends, or
circumstances after the date of this news release. Results from
case studies (reviews) may not be predictive of future results.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240717653834/en/
Stephanie Connolly media@extheramedical.com